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The natural history of human breast cancer. The relationship between
involvement of axillary lymph nodes and the initiation of distant
metastases
S. Koscielny, M.G. Le & M. Tubiana
Institut Gustave-Roussy, Rue Camille-Desmoulins, 94805 Villejuif, France.
Summary A method has been developed for determining the mean volume of breast cancer in women at the
time of the involvement of the first, second, third,... nth axillary lymph nodes. It has been found that the
proportion of patients with axillary involvement as well as the number of involved nodes increase
progressively with tumour size. This orderly involvement of axillary nodes is observed in all patient subsets
despite a wide spread of tumour volume at the time of invasion of the axillary nodes. This makes it possible
to compute for each patient or subset of patients the size of the tumour at the time of the first node
involvement, a parameter which characterises the propensity for nodal involvement. A strong correlation was
demonstrated between the propensity to lymphatic involvement and the probability of distant dissemination.
During tumour progression the capacity for lymphatic spread is on average acquired much earlier than the
capacity for haematogenous spread. For tumours of the outer quadrants, the volume at first axillary
involvement is smaller than for tumours located in the inner quadrants, whereas the tumour volumes at the
time of distant metastatic initiation are equal for the two tumour sites. The discrepancy between these two
observations shows that axillary involvement, while being a good index of the propensity of the tumour cells
to acquire the capacity for distant spread, is not the cause of this spread. From a clinical point of view, these
data show that the prognostic significance of axillary involvement can be further increased by taking into
account the size of the tumour. The data suggest that there is a continuum from slow growing disease with
late axillary involvement and late distant dissemination to the most aggressive subtype.
Involvement of axillary lymph nodes is probably the best
prognostic indicator in patients with breast carcinoma
(Contesso et al., 1977; Fisher et al., 1984) and is related to a
considerable increase in the excess mortality rate during each
follow-up period (Devitt, 1967; Brinkley & Haybittle, 1977).
Since, in most patients, distant metastases are the cause of
death, it would appear that invasion of axillary nodes is
strongly correlated with the probability of distant haemato-
genous dissemination. However, this correlation has never
been quantified. Moreover, the significance of the presence
of a given number of involved axillary lymph nodes is
probably different in a patient with a large tumour of 5cm
in diameter or a small tumour of 0.5cm in diameter (Fisher
& Slack, 1970; Tubiana et al., 1986) and this difference
deserves further investigation.
Recently, clinical interest in these problems has markedly
increased since the selection of patients in whom the
administration of adjuvant chemotherapy is justified requires
a good understanding of the natural history of human breast
tumours and a proper use of the relevant prognostic
indicators.
In previous papers, we have developed a computer method
for the analysis of the natural history of breast cancer in
order to extract, from a series of over 4,000 patients treated
at Villejuif, information which otherwise could not have been
obtained (Koscielny et al., 1984, 1985). The study of the
relationship between the size of the breast tumour and the
dissemination probability was made without any assumption
as to the pattern of tumour growth. The results showed that
there is a strong correlation between the logarithm of the
breast tumour volumes and the probability of distant
metastases (Koscielny et al., 1984). The time at which the
first distant metastases are initiated was also studied. The
method used was based on the adjustment of the distant
metastases detection curve as a function of time after
treatment (Koscielny et al., 1984, 1985). It was found that
the mean tumour volume at which the first distant metastasis
is initiated is markedly larger than that which was previously
evaluated by a simple backwards extrapolation to one cell of
the growth curve of the metastasis. This relatively late
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metastatic spread is consistent with the effectiveness of
mammographic screening of breast cancer; moreover the
predictions of the model are in good quantitative agreement
with the results of screening programmes (Koscielny et al.,
1985).
The aim of this paper is to assess the mean volume of
breast tumours at the time of the involvement of the first,
second, third, etc., axillary nodes, and to compare these
volumes with that of the tumour at the time at which the
first distant metastasis is initiated. Two main results were
obtained. For the first time, it was shown that in a human
tumour there is a strong correlation between the volumes at
the initiation of nodal metastases and of distant metastasis.
Furthermore it was shown that the prognostic significance of
axillary nodal involvement can be further increased by
taking into account the size of the tumour.
Methods
Population studied
This study is based on the registry of invasive breast
tumours of the Institut Gustave-Roussy (IGR) which has
previously been described (Koscielny et al., 1984). The
population included all the cases of invasive breast
carcinomas treated at the IGR from 1954 to 1979, excluding
the following: male patients, previously treated patients,
patients with clinical multifocal tumours and bilateral
primary breast cancers and patients for whom the diameter
of the primary tumour had not been measured on the
surgical specimen. The treatment protocol (Lacour et al.,
1968) did not change significantly during the entire period;
in particular adjuvant chemotherapy was not used during
this period. The 2,408 patients selected for this study were
treated by surgery first: either radical surgery or simple
mastectomy plus axillary dissection. The diameter of the
tumour was measured on surgical specimens and the volume
was calculated assuming a spherical volume. The number of
involved lymph nodes was assessed as previously described
(Contesso et al., 1977). In 941 patients included in various
prospective studies, an internal mammary chain dissection
was carried out and the number of involved lymph nodes
was registered. The location of the tumour in one of the four
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quadrants of the breast was prospectively registered in all
2,408 patients: 1,880 tumours were located in the outer
quadrants and 926 in the inner quadrants. Three hundred
and ninety-eight tumours, usually large ones, had to be
considered as central tumours and therefore registered in
both subgroups.
Relation between tumour size and nodal involvement
In a previous paper (Koscielny et al., 1984), we described the
method for computing the distribution of the volume V. of
primary breast tumours at the time at which the first distant
metastasis was initiated. This method, derived from Finney
(1964), is based on the analysis of the probits of the
estimated percentages of metastases and the mean value of
the logarithm of the tumour volume at initial treatment. It
assumes the existence for each tumour of a threshold volume
Vm at which the first metastasis is initiated. It was checked
that a logistic analysis gave similar results but the probit
method has the advantage of being based on the biological
concept of a threshold.
A similar method is used in this paper for determining the
distribution of breast tumour size at the time of axillary
nodal involvement. We first checked that, with increasing
tumour volume, the proportion of patients without nodal
involvement continuously decreases (Figure 1), which is
consistent with the concept of a threshold volume for nodal
invasion. Moreover, it can be seen in Figure 1 that the
proportion of patients with 1, 2 or n involved lymph nodes is
not significantly related to tumour volume. This supports a
model in which there is a continuous progression from no
lymph node involvement to involvement of one lymph node
and subsequently to involvement of two lymph nodes. Thus
the constancy in the proportion of patients with one lymph
node involved means that the inflow (progression from 0 to
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1) is equal to the outflow (progression from 1 to 2) (Figure
2). The validity of this conclusion is supported by Figure 3,
in which the cumulative proportion of patients with a
number of involved nodes >,1, >2, >3, etc., is plotted as a
function of the logarithm of tumour volume. When these
cumulative proportions are expressed on a probit scale
(Figure 3), the relationships are linear, indicating a log
normal threshold distribution.
The method used for assessing the distribution of the
volumes of the primary tumour at the time of the
involvement of the first, second,... nth axillary lymph node
was based on equality between the proportion of tumours
bearing at least n involved lymph nodes and the proportion
of tumours with a volume at treatment greater than at the
initiation of the nth node (Figure 3). The median tumour
volumes Vi, V2,... PV at which 50% of the tumours have a
number of involved lymph nodes equal to or greater than 1,
2,... n lymph nodes are estimated from the regression lines
(Finney, 1964).
Since in Figure 3 the curves appear to be linear and
parallel, the increase in tumour volume between initiation of
the nth node and node n+1 can be estimated by the ratio kn
between the volumes R' +1 and R' (k.= l' +1/P.). In order to
evaluate the error which could be introduced if the curves
were not linear or not parallel, simulations were performed.
The results of these simulations are described in the
Z nn = 1 n 2 | 3
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Figure 2 Progression of axillary nodal involvement during
tumour growth. When a new nodal involvement occurs, the
tumour progresses from the subset of patients with n involved
nodes to the subsets of patients with n+1 involved nodes. V1,
V2... Vl' are the median tumour volumes at time of nodal
involvement. iV1, ,uV2, etc., are mean volumes of the tumour with
1, 2,... n, involved lymph nodes.
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Figure 1 Variations as a function of the tumour diameter in the
proportions of patients with breast cancer with 0, 1, 2 and 3
involved axillary nodes. With increasing tumour volume, the
proportion of patients without nodal involvement (n=O) con-
tinuously decreases.
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Figure 3 Cumulative proportions of patients (in probit scale)
with 1 or more than 1, 2 or more than 2, etc., involved axillary
lymph nodes as a function of the breast tumour volume at
surgery (logarithmic scale). Data concerning >6 and >7 axillary
nodes have been omitted for clarity.
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Appendix and show that the errors that can be introduced
by these assumptions are negligible.
Thus. in each individual it can be assumed that as the
tumour grows. the number of involved nodes progressively
increases; on the average the tumour volume at the initiation
of lymph node n+l is equal to V,1 = V.k., where V. is the
tumour volume at the initiation of the nth node. Two
hypotheses have to be considered: either the value of k, is
constant for all patients or k. can var-y from patient to
patient around a mean value k,. Simulations (Appendix)
show that the data can be fitted satisfactorily using either of
these assumptions. We have, in the following calculation.
used the first since it is much simpler.
Hence in a patient with a tumour of a given volume and
with a given number n of involved lymph nodes, one can
compute what had been its volume V1 at the initiation of the
first involved lymph node. The method used for this
computation is based on the assumption of a progressive
increase in the number of involved nodes. In the model
(Figure 2) the mean volume pV. of the tumours with n
involved lymph nodes is on the log scale at mid distance
between 1V. the volume at the initiation of node n. and Vn-,1.
the volume at the initiation of node n+ 1. It is therefore
possible to estimate, in a given subset of patients, the
expectancy of the volume V1 at the initiation of the first
involvement by dividing the actual volume V by the
coefficient:
kn.n- 1 ki k\kln
=11
The estimation of VI is of great interest since V1 expresses
the propensity for lymph node involvement of a given
tumour. It combines in one figure two pieces of information:
the size of the tumour and the number of involved lymph
nodes.
The constants kn and therefore V, cannot be computed by
this method in patients without lymph node involvement or
when the number of involved lymph nodes is greater than 7.
For those patients the following methods were used. Patients
with no axillary lymph node involvement are those in whom
the tumour size at treatment V is smaller than V1. For such
patients there are two extreme possibilities; either V is only
slightly smaller than V1 (V+z = V1) or V1 is extremely large
(V1 = x). Thus the expected value of V1 is
E( 11)= X xf(x)dx f f(x)dx
w-here f(x) is the distribution function of V1. This
distribution is log-normal. The standard deviation a and the
mean value plog V1. which allow calculation of E(V7). have
been estimated from the regression line between the
proportion of tumours with at least one involved axillary
node and tumour volume at treatment.
A similar type of reasoning can be used for tumours with 7
nodes or more involved. The volume V_ is in the range 0 and
V-z: the expected value E(V ) is therefore:
V ,
E(V-)= jxf(x)dx I f(x)dx
0 0
where f(x) is the distribution function of V7. For these
patients the value of V, is:
E(V1)=E(V-) (1 ki)
Simulations were carried out in order to check the validity of
the model and to estimate the errors. The results are given in
the Appendix.
Tumour rolume at the initiation of the first distant metastasis
(V.)
The value of the variance c2log Vm is supposed constant in
the various groups of patients defined by the tumour volume
(V) at treatment and also the number of involved axillarv
nodes. Variation in m2og Vm. which might introduce bias. is
discussed in the Appendix and shown to be negligible.
Therefore. in a given group, the mean tumour volume at
metastasis initiation (p log V.) can be calculated as a function
of the tumour size and of the proportion of patients with
distant metastases (p) for tumours of this size. using the
relation:
plog V. =log V-(a log Vmprobit(p) -5).
The tumour volumes at the initiation of the first axillary
node (V1) and at the initiation of the first distant metastasis
(V.) were calculated for 20 groups of patients (four classes of
axillary involvement: without lymph node involvement, 1-3
invaded nodes. 4-7 invaded nodes, n>8. and five classes of
tumour diameters: D< 1.5: 1.5 D<2.5: 2.5 D<3.5:
3.5AD<4.5: D>4.5cm). The relationship between V1 and
Im was studied using a least square method, with a weight-
ing factor equal to the inverse of the variance of the
proportion of patients with metastases. Separate calculations
were also made for tumours located in the inner or the outer
quadrants of the breast.
Results
Figure 3 displays the proportion of tumours with )n
involved nodes, as a function of tumour volume measured on
the surgical specimen. Regression lines were calculated for
values of n ranging from 1 to 7: their slopes are not
significantly different (values ranging from 0.202 to 0.246.
mean 0.224); thus the variances of the distributions of the
logarithms are approximately the same. The constancy of the
slope in Figure 3 is one of the assumptions on which the
above-described method is based. For tumours of less than
5cm in diameter, the relationship appears to be linear. This
linearity means that distributions of the volume are log-
normal. However, the proportion of nodal involvement in
the group of tumours larger than 5 cm is less than the
predictions obtained from the regression. This smaller
incidence of nodal involvement is probably due to the
selection of the patients referred to the surgeons. selection
which introduces a strong bias, as most of the patients with
large tumours received preoperative radiotherapy (Lacour et
al.. 1968; Sarrazin et al.. 1982). This is why. for the study of
the relationship between the tumour volume and the
probability of nodal involvement, tumours of a diameter
larger than 5cm were not included.
Using these linear relationships, one can assess by extra-
polation the proportion of patients with involved axillary
nodes for very small tumours. However, there are few data
regarding this proportion for tumours of less than 1 cm in
diameter (Tabar et al., 1987; De Metz & Porter, 1987) and
any comparison would be premature.
The median volumes of the tumour at the initiation of the
1st. 2nd, etc., axillary node were calculated according to the
method described above. The results are given in Table I for
the whole group of patients and are depicted in Figure 4 for
three subsets of patients: those with a median value of V1
equal to V,, V, being the value at which in the whole group
50'X, of the patients have one or more involved axillary
nodes; those with a value equal to V1-a or V1+a where a is
the square root of the variance of the distribution. In Figure
4 the primary tumour doubling times (DT) of the three
subsets of patients were estimated from metastasis
appearance curves as a function of the delay after initial
treatment. The method used for this estimation. to be fully
described in another paper, is based on the assumption that778 S. KOSCIELNY et al.
Table I Mean tumour volume at initiation of axillary node
All patients Outer quadrants
(n=2,408) (n=1,880)
0>1 1.21 ml
(1.32cm)
[0.97-1.51 ml]
1>2 12.3ml
(2.86cm)
[10.1-14.9ml]
2>3 48.7ml
(4.53cm)
[37.1-63.7ml]
3>4 129ml
(6.27cm)
[91.8-181 ml]
4>5 243ml
(7.74cm)
[164-358ml]
5>6 531 ml
(10cm)
[337-831 ml]
6>7 916ml
(12cm)
[555-1,500ml]
1.15ml
(1.30cm)
11.2ml
(2.76cm)
43.9ml
(4.38cm)
115ml
(6.03 cm)
220ml
(7.48cm)
489ml
(9.77cm)
904ml
(12cm)
In parentheses, corresponding diameters;
confidence intervals of the mean.
Inner quadrants
(n =926)
1.36ml
(1.37cm)
15.7ml
(3.11 cm)
58.1 ml
(4.80cm)
156ml
(6.67cm)
323ml
(8.51 cm)
631 ml
(10.64cm)
1,050ml
(12.6cm)
in brackets, 95%
12.4
5.8-
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the time interval between treatment of the primary tumour
and the clinical emergence of the distant metastasis is a
function of V. (the tumour volume at the initiation of the
metastasis), V the size of the tumour at treatment, and the
volume doubling times of the primary tumour and of the
metastasis. V and V. being respectively measured and
computed, the ratio of the DT of the primary tumour and
that of the metastasis being given by the analysis of the
published data (Koscielny et al., 1985), the mean value of the
DT of the primary tumour can be calculated.
The median V1 value was also studied for the subgroups of
patients with the tumour located in either the outer or the
inner quadrants. The values of the volume at the initiation of
the first axillary lymph node is approximately 1.5 times
larger in patients with a tumour located in the inner
quadrants than in those with tumours located in the outer
quadrants (Table I). However, the volume at initiation of the
first distant metastasis is not statistically different in the two
subgroups, although it is, if anything, slightly smaller for
inner tumours (Table II).
Patients with inner quadrant tumours have a much higher
probability of involvement of the internal mammary chain
than patients with outer tumours (Lacour et al., 1976;
Handley, 1972). This is consistent with what is known about
the lymphatic pathways of the breast tumours. The
relationship between the size of the primary tumour and the
proportion of patients with an involvement of the internal
mammary chain was established on the 646 patients with a
tumour located in the inner quadrants who had undergone a
dissection of this chain within the frame of controlled studies
(Lacour et al., 1976). The median tumour volume at the
initiation of the first internal mammary node was 243ml
(confidence interval 117-506) and of the second node
2,031 ml (699-5,900), the corresponding diameters being
7.9cm and 15.8cm respectively. Thus the volume of the
primary tumour for which there is an involvement of the
internal mammary nodes in 50% of patients is approximately
100 times larger than the corresponding value for the axillary
nodes. The average number of involved axillary nodes is
slightly greater than five when the first internal mammary
node is invaded. The ratio between the volume of the
primary tumour at the initiation of the 1st and the 2nd node
are similar for axillary and internal mammary nodes.
Moreover, the slope of the curve relating the proportion of
nodal involvement to the size of the tumour is identical for
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Figure 4 Schematic description of the natural history of breast
cancer in three subsets of patients. Vertical axis: tumour volume
(logarithmic scale) expressed by tumour diameter; horizontal
axis: time. Zero time is the time at which the breast primary
tumour, assumed to be spherical, has reached a clinically detect-
able size (tumour volume = 1 ml). Vertical arrows indicate the
median size of the tumour at the time of the first, second, etc.,
axillary lymph node involvement. Horizontal arrows (M) indicate
the median size of the tumour at the time of distant metastatic
dissemination. Tumour growth pattern is assumed to be expo-
nential in keeping with previous data. The three groups of
patients are defined by the size V1 of the tumour at the time of
first axillary lymph node involvement. V1 is the median size for
the whole group of operable patients. a is the standard deviation
of V1. Thus the (V' -a) group corresponds to patients with early
first lymph node involvement and (V1 +a) to that of late
involvement. The tumour doubling times for the three groups
were calculated according to the method described in the text.
the two lymphatic areas, since its value for internal
mammary node involvement is 0.225.
Table III shows that among patients with tumours located
in the inner quadrants, there is a much higher propensity for
axillary node involvement in patients with invaded internal
mammary nodes than in patients without internal mammary
invasion. Thus there is a highly significant correlation
between the propensity for axillary and internal mammary
node invasions.
Among the 20 subsets of tumours defined by the five
classes of tumour volumes and the four classes of the number
of involved axillary lymph nodes, there is a strongHUMAN BREAST CANCER 79
Table II Mean tumour volume at initiation of first distant metastases (V50)
All tumours Outer tumours Inner tumours
12.32ml 13.82ml 9.17ml
95% confidence interval of the mean 9.05 16.8 ml 9.6-19.9ml 5.94-14.2ml
Table III Among patients with tumour located in the inner
quadrants, proportion of patients with a given number of invaded
axillary nodes according to the internal mammary chain status
Percentage ofpatients with
invaded axillary nodes
0 1-3 4-7 ~ 7
Patients without 31.7% 35.9% 18.3% 14.1%
internal mammary
nodes involvement 68.3%
Patients with internal 8.8% 30.4% 26.3% 34.5%
mammary nodes Y
involvement 91.2%
correlation between the mean volumes of the tumours at
initiation of the first axillary node and of the first distant
metastasis. The weighted correlation coefficient is equal to
0.934. Figure 5 displays the results which correspond to the
following regression line:
log V. =alog V, +b.
In patients with outer tumours, the best fit is obtained with
a = 0.479 and b = 2.85. In patients with inner tumours, the
best fit is obtained with a = 0.51 and b = 2.32. However, the
values of a in inner or outer tumours are not significantly
different whereas the values of b differ significantly.
In this relationship between log V. and log V,, the slope a
provides an estimate of the correlation (R,iv.
= R) between
the value V, and V,, in a given patient. The relationship
between the correlation and the slope a is:
R = a(i log Vlur log V.,)
= 0.5(4.555/4.836)
= 0.47.
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Figure 5 Relationship between the breast tumour volume at
metastatic dissemination and the breast tumour volume at the
time of involvement of the first axillary lymph node. The
volumes were calculated according to the method described in
the text for 20 subgroups of patients defined by the tumour size
at initial treatment and the number of involved axillary nodes
(see text). However, it is noteworthy that there are, in the subsets
with a small tumour volume, only small numbers of patients at
involvement of first lymph node. This may explain the scatter for
these subsets.
Thus for a given value of V1 the residual variance of Vn~is
equal to:
a'2logI/./log V1 =a'log Vrn(1 -R2) =0.78a2 log 1<,.
Hence among patients with a given value of log V, the
variance of log V. is reduced by 22% (Figure 6).
Whatever the location of the tumour in the inner or the
outer quadrants, the variance of log V., is identical. This
would suggest that the correlation between the propensities
for axillary lymph node involvement and for distant
metastases are the same for inner and outer tumours. The
significant difference observed for the value of the parameter
b between inner and outer tumours is probably related to the
later involvement of the axillary nodes in tumours located in
the inner quadrants.
Whatcver the location of the tumour, when the volume of
the tumour at initiation of the first node is increased 100-
fold, the volume of the tumour at initiation of the first
distant metastasis is increased approximately 10-fold (Figures
4 and 5). Both events are very rare: for example on average
the tumour volume increases approximately 9-fold from the
time at which the first axillary lymph node is involved to the
time at which a second node is involved.
Vi 0OSl*
Figure 6 Distribution (density of probability) of the tumour
volume at metastatic dissemination for the whole patient popu-
lation and for a patient population having the same tumour
volume at initiation of the first axillary lymph node.
779780 S. KOSCIELNY et al.
Table IV Proportion of patients (observed and calculated) with distant
metastases according to the diameter of the breast tumour and the number of
involved axillary nodes
All
patients Tumour diameter 1.25cm Tumour diameter 2.25cm
Axillary
nodes Obs. Calc. Obs. Calc. Obs. Calc.
0 0.251 0.261 18.6+ 4.5 20.8+0.2 23.3+ 5.8 27.8+0.3
1-3 0.461 0.461 37.6+ 7.9 39.1 +0.3 48.0+ 8.8 45.7+0.3
4-7 0.582 0.593 42.7+ 13.5 51.8+0.4 52.8+ 10.8 57.4+0.4
>8 0.738 0.705 71.6+ 15.6 60.8+0.6 71.4+ 10.7 68.2+0.5
The proportion of patients with distant metastases can be
estimated according to the number of involved axillary nodes
and the tumour volume. As an example, Table IV compares
in the overall population 2 subsets of patients, the first one
with tumour diameter less than 2cm (mean 1.25cm) and the
second with a tumour diameter between 2 and 3cm (mean
2.25cm). The overall correlation between observed and
calculated values is highly significant.
Discussion
The natural history of human breast cancers is a topic which
has been much discussed but for which quantitative data has
been scanty until the present studies (Tubiana & Koscielny,
1987; Koscielny et al., 1984, 1985). The results presented in
this paper quantify the concept of an orderly involvement of
axillary nodes during tumour growth. Despite the wide
spread of tumour volume at the invasion of the first axillary
lymph node, the ratio of the tumour volume at invasion of
the first and the second or the third lymph node is identical
in all subgroups of patients. Thus the progressive
involvement of axillary nodes follows the same probabilistic
law in all patient subsets.
Another striking result is the demonstration of a strong
correlation between the propensity for lymphatic involvement
and the probability of distant haematogenous dissemination.
It has been possible to characterise the propensity for lymph
node invasion by the volume V1 of the tumour at first node
involvement. This volume was computed and found to be
significantly correlated with the tumour volume (Vm) at
metastatic spread in all subsets of patients (Figure 5). From a
fundamental point of view, this is an important and an
original result. It is consistent with recent findings showing
the independent prognostic impact of tumour volume and
number of positive nodes (Koscielny et al., 1984; Atkinson et
al., 1986) and provides a basis for their interpretation.
The present results show that, on average, during tumour
progression the capacity for lymphatic spread is acquired
much earlier than the capacity for haematogenous spread.
The acquisition of the capacity for lymphatic spread appears
to be an event which occurs more frequently than the
acquisition of the capacity for haematogenous spread.
It should be pointed out that the delay between the
migration of the neoplastic cell which originates a colony in
the axillary lymph nodes and that which originates distant
metastases is even longer than depicted in Figure 4 and in
Tables I and II. The method for the determination of the
tumour size at initiation of first metastasis (Vm) estimates its
size at the time of the seeding of the neoplastic cell.
Conversely, a tumour cell colony in a lymph node becomes
detectable when the number of cells in the colony reaches
103 to 105, so the seeding of the first neoplastic cells occurred
at least 10 doubling times earlier. However, this methodo-
logical bias has no impact on the relative sizes of the
tumours at the time of the first, second, third, etc., lymph
node involvement in the various subgroups of patients.
Three groups of tumours are compared in Figure 4:
,tvierrge tumours (V1 = /), tumours with a high propensity to
lymphatic spread (V1 = V1a-), and tumours with a low
propensity (V, =V1 +a). The volume of the primary tumour
at first nodal involvement is 100-fold larger in the median
subset than in that with a high propensity and 100-fold
smaller than in the subset with a low propensity. The
differences in the volume at initiation of distant spread are
10 times smaller. These considerable differences are
consistent with the concept of biological predetermination of
cancer progression. Moreover these data (Figures 4 and 7)
show that V1 is a useful variable for quantifying this
predetermination. The present analysis is not, however,
consistent with the concept that breast cancer is a
conglomerate of different diseases with widely different
natural histories. It rather suggests that there is a continuum
from slow growing disease with late axillary involvement and
distant dissemination to the most aggressive, rapidly growing
subtype.
Even in the worst prognostic subset, lymphatic and
haematogenous spread are extremely rare events. For
example, assuming a cell loss factor of 75% in a tumour
belonging to the intermediate subset, then out of 2 x 1010
cells which were born in the tumour, only one cell will
migrate to a node and initiate the first nodal neoplastic
colony. Moreover the birth of more than 1011 cells will occur
before another cell will initiate the second neoplastic colony
in another node. For haematogenous spread, the first colony
is initiated after 1012 mitoses in the primary tumour.
As a consequence of this study, the prognostic significance
of axillary lymph node involvement can be better interpreted
and assessed. Intuitively, clinicians know that the prognostic
significance of a given number of involved lymph nodes is
not the same for small and large tumours. Fisher et al. (1970)
and Handley (1972) reported that an increasing size of the
primary tumour is usually correlated with an increasing
likelihood of node invasion. However, these observations
remained qualitative. The present data help one to
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Figure 7 Distribution (density of probability) of the tumour
volume (in ml) at the time of distant metastatic dissemination in
two of the three subsets of patients defined in Figure 3. The
mean volume of the primary tumour at dissemination differs
very significantly in the two groups, but there is in the three
groups a wide spread of individual values and therefore a
considerable overlapping of the three distributions.
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understand some apparently paradoxical observations
reported on breast cancers.
For tumour diameters ranging from 0.1 to 2cm, the
predictions of the model could be compared with the few
available data (Bedwani et al., 1981; De Metz et al., 1987;
Tabar et al., 1987). However, the validity of this comparison
is debatable. Some detectable tumours were not operated, for
example because they were associated with palpable axillary
nodes, or fixation to the thoracic wall or inflammatory
reaction. These non-operable tumours are not included in
this study, which comprises only tumours treated by surgery.
Conversely, tumours detected by screening are all operated
upon. The biological characteristics of tumours which remain
operable when they reach a detectable size may differ from
that of the non-operable tumours of the same size.
In a previous study, we showed that, in a population of
patients, the probability of dissemination, expressed by the
percentage of patients with distant spread, increases as a
function of the tumour volume (Koscielny et al., 1984). This
increase can be interpreted by the growing proportion of
tumours that are larger than their threshold volume Vm at
which the first distant metastasis is initiated. The distribution
of V. values is log normal and the wide spread of the
individual values corresponds to a large variance of the
distribution (Figure 6). This distribution can be characterised
by two parameters, the median (V50) and the variance.
Previous data showed that histological grade and number of
involved lymph nodes markedly influence the V50. However,
the influence of these two variables on the variance of the Vm
distribution is relatively small. The present data show that
the variance is reduced by about 20% when the size at the
involvement of the first lymph node is taken into account
(Figure 6). Thus this parameter is more informative than the
number of involved lymph nodes but is still associated with
only one-quarter of the variance. Therefore the search for
other parameters associated with this large variance should
continue.
The comparison between tumours located in the inner and
outer quadrants of the breast shows that involvement of an
axillary node is not a frequent step for metastatic spread
since the volume at distant metastatic dissemination is the
same for the two subsets of tumours, whereas the volume of
the tumour at first axillary involvement is smaller for outer
tumours then for inner tumours. This observation does not
favour the so-called cascade model (Viadana et al., 1978) and
the traditional view of distant spread which assumes that the
lymphatic system is the main pathway (Robbins & Cotran,
1979). Indeed, the data strongly suggest that the liability, for
either lymphatic or haematogenous spread, although related,
are nevertheless not linked by a causal relationship. Their
correlation is probably due to the fact that both are caused
by the characteristics of the neoplastic cells, in particular
their genetic instability (Tubiana, 1986). The concept of
tumour-host relationship does not appear to be required for
the interpretation of the data.
This conclusion, namely that axillary involvement is a
good index for the propensity of tumour cells in acquiring
the capacity of haematogenous spread but not the cause of
this spread, is consistent with the concept developed by
Fisher (1984). Furthermore it is noteworthy that loco-
regional recurrence rates are also much higher in patients
with axillary involvement and are related to the number of
invaded nodes (Devitt, 1967; Tubiana & Sarrazin, 1987).
Hence lymphatic spread is also a signpost of the migration of
tumour cells into the surrounding tissues. The study of
oncogenes and of the biology of the tumour cells should help
us to understand better the underlying molecular
mechanisms.
The probabilities of axillary invasion and of internal
mammary involvement are also highly correlated (Table III),
which is in keeping with previous studies (Lacour et al.,
1976). Among patients with inner tumours, the data show
that only 9% of the patients with an invaded internal
mammary chain are without axillary involvement, as
compared to 32% without axillary involvement when the
internal mammary chain is not involved. Among operable
patients with tumours of the inner quadrants and with
involved internal mammary, the model predicts that
approximately 45% of them have no distant metastases. This
result is consistent with the data concerning our patient
population and is in agreement with the effectiveness of the
treatment of the internal mammary that we have recently
emphasised (Lacour et al., 1976; Tubiana et al., 1986;
Arriagada et al., 1988).
Finally, one of the interesting features of the model is the
inclusion into the evaluation of the probability of distant
metastases of other factors besides VI, such as the labelling
index, histological grade, oestrogen receptors, etc. Some are
highly correlated with VI, and so will probably add little to
the accuracy with which the probability of spread is
presently determined. However, others, such as labelling
index or tumour growth rate (Tubiana & Koscielny, 1988),
have independent prognostic significance, so one might
expect that they could improve the validity of the
predictions. This is a point that we shall discuss further in a
subsequent paper.
Appendix
Precision of the estimation of VI
Simulations have been performed in order to estimate the
precision of the calculated volume at the first node
involvement (V1) in groups of patients defined by tumour
volume at treatment and number of involved axillary lymph
nodes (see Methods).
These simulations can be described as follows: for each
tumour, the tumour volume at treatment and at the first
lymph node invasion are taken at random, according to the
observed distributions for these variables. These two volumes
are taken as independent. The tumour volume at the time of
the first metastasis initiation is calculated according to the
volume at the first node invasion, assuming a positive
correlation (Ri,,m) =0.5 (as found in the results) between
these two volumes. These values of V1 are termed, below, the
exact ones.
The volumes at the successive lymph nodes invasions are
thereafter calculated as a function of the volume at the first
lymph node invasion. The volume at node n is equal to the
volume at node n-I multiplied by a factor k.. The value
kn is defined by the data for the relationships between
tumour size and the number of involved axillary lymph
nodes. The values of kn can be supposed either the same for
the tumours or varying from one tumour to another. If kn is
assumed variable, each kn value is taken at random from a
uniform distribution with an interval 0-2y(kn). For example,
kn equal to 0 means that initiation of nodes n and n+1
occurs at the same time.
The tumour volumes at the time of successive node
involvements and the volume at treatment are calculated.
The number of involved axillary nodes at the time of tumour
treatment is obtained by comparing the volume at treatment
to the volumes at the different node invasions. The 'apparent'
tumour volume at the first node involvement is therefore
calculated with the procedures described in the article,
according to the volume at treatment and the number of
involved nodes.
This procedure is iterated for 2,408 tumours (the size of
our population). In order to calculate the values of the
means of the exact values and of the apparent values. The
parameters of the distribution of the mean value of exact V,
and of apparent V1 are estimated from the simulation of
1,000 populations.
The difference between the apparent mean volume at the
initiation of the first lymph node and the exact value is less
than 0.1%. The variance of the estimation of the mean is less782 S. KOSCIELNY et al.
than the variance of the exact mean, especially in the
subgroups with no involved lymph node.
The estimation of the parameters of the relationship
between the volume at the initiation of the metastases and at
the initiation of the first lymph node is not affected by the
variability on the ratio k. A possible bias in the analysis can
be caused by variation of the variance of the tumour volume
at the initiation of the first metastasis (V.) in the various
subgroups of tumours. This variance is assumed to be the
same in the subgroups as in the whole population. However,
as V1 and Vm are correlated, the variance of V. depends on
the variance of V1. The variance of the tumour volume at
metastasis initiation is almost the same in the various groups
and nearly equal to the variance estimated for the whole
population. The variance of the tumour volume at the first
lymph node initiation is relatively large in each group.
In fact, the number of involved nodes only gives
information concerning the range of volume values including
V1. Consequently, the variance of V1 estimation is relatively
large. Moreover, the variance of the volume at the first
metastasis initiation in the different groups only depends. in
this context. on the variance of V1 in the corresponding
group.
O2Vm/ V1 =2V.[I-R2V1 Vm(I T2 V1, a2V1)]
where a2V11 is the variance of V1 in the subgroup. As i2V11
very close to a2V1. the value of a2I',, V1 in the various
groups can be considered as equal to the value of a2 V
estimated for the whole population.
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